Has anyone run the new v3 flowcells and reagents on the HiSeq2000? We need to purchase more reagents but I am hesitant to switch over without feed back from other people.
-
-
We haven't but will be soon. As I understand it, V3 will soon be the only option from Illumina. I actually have a question about how much library to load on the V3 kits to get in the range of 800k clusters/mm^2. On the V2 flow cells, we get about 600K with 9pm loaded. We titrated the load on the V2 lanes and the resulting cluster densities increased linearly with the load, to a point. In moving to a larger lane, I don't think the same would be true. Does anyone have experience with this? -
We'll be transitioning to v3 soon as well. Our FAS suggested starting at 12pM.Comment
-
Note the optics of your HiSeq have to be recalibrated before running v3 flowcells and reagents. The Y coordinates in the config file needs updating by using a beaded flow cell by your service engineer.Comment
-
Something to make a note of: The quality table for the new, v3 kits has a range from “B” to “m" per Illumina tech support.Comment
-
So now the highest quality value is 45? What was it previously?
--
PhillipComment
-
It was 40 (http://en.wikipedia.org/wiki/FASTQ_format).Originally posted by pmiguel View PostComment
-
Well the unavoidable cheap shot at Illumina is: kind of like having an amplifier that goes up to "11"?
Looks like the highest ordinal for a printable ascii char is "62" for "~". Roughly one error in 4 million base calls. For a 33 offset encoding you can reach a quality score of "93". One error in 8 trillion base calls.
--
PhillipComment
-
NGS has revolutionized clinical microbiology by offering new ways to identify and surveil pathogens without prior knowledge of the target. One popular approach is 16S rRNA and ITS amplicon sequencing, which targets specific microbial markers. But studies are increasingly incorporating shotgun metagenomics, a technique that sequences all DNA from a sample without targeting specific microbial markers. This approach allows more detailed taxonomic classification, detection...Today, 06:46 AM -
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM
Comment